Paulzen, Michael and Schoretsanitis, Georgios and Stegmann, Benedikt and Hiemke, Christoph and Gruender, Gerhard and Schruers, Koen R. J. and Walther, Sebastian and Lammertz, Sarah E. and Haen, Ekkehard (2017) Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 76. pp. 101-106. ISSN 0278-5846, 1878-4216
Full text not available from this repository. (Request a copy)Abstract
Objectives: To investigate in vivo the effect of low-potency antipsychotics on metabolism of risperidone (RIS). Methods: A therapeutic drug monitoring database containing plasma concentrations of RIS and its metabolite 9-OH-RIS of 1584 patients was analyzed. Five groups were compared; a risperidone group (n = 842) and four co-medication groups; a group co-medicated with chlorprothixene (n = 67), a group with levomepromazine (n = 32), a group with melperone (n = 46), a group with pipamperone (n = 63) and a group with prothipendyl (n = 24). Plasma concentrations, dose-adjusted plasma concentrations (C/D) of RIS, 9-OH-RIS and active moiety (RIS + 9-OH-RIS; AM) as well as the metabolic ratios (9-OH-RIS/RIS; MR) were computed. Results: Differences in plasma concentrations were detected for AM and RIS. Pairwise comparisons revealed significant findings; RIS plasma concentrations were higher in co-medication groups than in monotherapy group. Chlorprothixene-and prothipendyl-medicated patients demonstrated no other differences. In the levomepromazine and melperone group plasma and C/D concentrations of AM and RIS were higher, while MRs were lower. For pipamperone, differences included higher C/D values of RIS and lower MRs. Conclusions: Alterations of risperidone metabolism suggest pharmacokinetic interactions for levomepromazine and melperone. In the pipamperone-group, lower MRs as well as higher plasma and C/D levels of RIS suggest potential interactions. (C) 2017 Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CYTOCHROME-P450 2D6; LEVOMEPROMAZINE; SCHIZOPHRENIA; MELPERONE; METABOLISM; CYP2D6; 9-HYDROXYRISPERIDONE; HALOPERIDOL; QUETIAPINE; INHIBITOR; Antipsychotics; Risperidone; Psychopharmacology; Pharmacokinetics; Therapeutic drug monitoring |
| Subjects: | 100 Philosophy & psychology > 150 Psychology 500 Science > 570 Life sciences |
| Divisions: | Psychology and Pedagogy > Institut für Psychologie Chemistry and Pharmacy > Institute of Pharmacy > Pharmacology and Toxicology (Prof. Schlossmann, formerly Prof. Seifert) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 14 Dec 2018 13:10 |
| Last Modified: | 19 Feb 2019 10:15 |
| URI: | https://pred.uni-regensburg.de/id/eprint/717 |
Actions (login required)
 |
View Item |
